Stiripentol as Treatment for Epileptic Seizures
Bachelor thesis
![Thumbnail](/ntnu-xmlui/bitstream/handle/11250/3132037/no.ntnu%3ainspera%3a187263275%3a93099691.pdf.jpg?sequence=5&isAllowed=y)
Permanent lenke
https://hdl.handle.net/11250/3132037Utgivelsesdato
2024Metadata
Vis full innførselSamlinger
- Institutt for kjemi [1397]
Sammendrag
I denne oppgaven skal stiripentols mekanismer mot epilepsi diskuteres. Stiripentol er et legemiddel mest brukt mot Dravet syndrom, en sjelden barneepilepsi med høy dødsrate. Mekanismene mot epilepsi består av enzyminhibering, GABAA modulering og inhibering av andre antiepileptiske legemidlers metabolisme . Resultater av dyre- og menneskestudier vil drøftes. Årsaken til stiripentols effekt mot langvarige anfall (status epilepticus) er diskutert. Farmakokinetikken og metabolismen til (R)-og (S)- stiripentol er inkludert i diskusjonen. Basert på kliniske studier, bør stiripentol gis rasemisk siden enantiomerene hemmer hverandres metabolisme. Stiripentol er mest potent i behandling med valproat og klobazam. Stiripentol bør fortsette å bli anbefalt i bruk mot langvarige anfall. Cannabidiol er en mulig adjuvant behandling mot Dravet syndrom. In this paper stiripentol’s mechanisms against epileptic seizures will be discussed. Stiripentol is a drug used for treating Dravet syndrome, a rare childhood epilepsy with a high mortality rate. Stiripentol’s mechanisms include enzyme inhibition, GABAA modulation and inhibition of other antiepileptic drugs. The results of animal and human studies will be considered. The cause for its high potency against prolonged seizures (status epilepticus) is examined. The pharmacokinetics and metabolism of (R)-and (S)-stiripentol are also included. Based on the studies, stiripentol should be marketed as a racemate since the enantiomers inhibit each other’s metabolism. Stiripentol is clinically most potent when taken with valproate and clobazam. It should also keep being recommended for status epilepticus, especially in young children. Cannabidiol is a potential adjuvant treatment for Dravet syndrome.